Research Analysts Offer Predictions for STOK FY2026 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Stoke Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($2.51) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $23.20.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK traded up $0.32 during midday trading on Tuesday, reaching $11.82. 500,444 shares of the company's stock were exchanged, compared to its average volume of 700,120. The stock has a market capitalization of $645.34 million, a PE ratio of -5.63 and a beta of 1.09. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $17.58. The business's fifty day moving average price is $9.07 and its two-hundred day moving average price is $9.66.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after acquiring an additional 4,512 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Stoke Therapeutics during the fourth quarter valued at $1,423,000. Bank of New York Mellon Corp raised its stake in shares of Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of Stoke Therapeutics during the fourth quarter valued at about $139,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Stoke Therapeutics by 123.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock valued at $1,053,000 after buying an additional 52,813 shares during the period.

Insider Buying and Selling at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,748 shares of company stock worth $225,687 over the last ninety days. Company insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.